Article

Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study.

Department of Neurological Sciences, University of Bari, Italy.
Journal of the Neurological Sciences (Impact Factor: 2.24). 01/2007; 250(1-2):45-9. DOI: 10.1016/j.jns.2006.06.027
Source: PubMed

ABSTRACT The El Escorial and the revised Airlie House diagnostic criteria for amyotrophic lateral sclerosis (ALS) were introduced to select patients for clinical trials. Heterogeneity of clinical presentation at onset and delay in diagnosis may decrease the likelihood for trial entry.
Identify risk factors for delay in the diagnosis and trial exclusion.
ALS incident cases were identified with El Escorial (EEC) and Airlie House criteria (AHC) through a population-based registry established in Puglia, Southern Italy, in the years 1998-99.
130 ALS incident cases were diagnosed with a median interval between onset of symptoms and diagnosis of 9.3 months and not different across both EEC and AHC categories. Twenty percent of cases were not eligible for clinical trials according to the AHC. About 5% of subjects in this series died with only lower motor neuron signs. Predictors for delay in the diagnosis were age between 65 and 75 years and spinal onset while fasciculations and cramps as first symptoms were predictors of exclusion from trials.
In this population-based series, diagnostic delay was longer in subjects with spinal onset and age between 65 and 75 and fasciculation as first symptoms. About 80% of incident cases were trial eligible with AHC criteria. However, a significant number of subjects with ALS, characterized by a limited spread of signs, were not trial eligible while alive.

0 Bookmarks
 · 
61 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies suggest amyotrophic lateral sclerosis (ALS) prevalence, incidence, and age of onset are heterogeneous across populations. These include studies from South America (SA) where lower prevalence, earlier onset, and reduced survival time of ALS are reported. However, the scarcity of epidemiological and clinical data confounds effective comparison. To investigate ALS incidence in the predominantly admixed population of Ecuador, we analyzed patient data. We analyzed case data from two major hospitals. To confirm diagnosis, we evaluated clinical and EMG examinations in a cohort of patients. For 2000-2012, we found 116 patients with ALS diagnosis in the two hospitals. Crude incidence was 0.2-0.6 per 100,000. Median age of onset was 54.3 (+ 15.06 SD). Clinical re-evaluation found misdiagnosis in three cases in the cohort. In conclusion, ALS incidence in the Ecuadorian hospital population is in accord with rates reported in recent studies for other admixed populations, and lower than that in the United States and Europe. Our study found that appropriate EMG administration and interpretation for the purposes of supporting a diagnosis of ALS with current consensus guidelines prevent adequate use of this test as an essential tool in the evaluation and diagnosis of ALS. Training for required standardization in Ecuador is recommended.
    Amyotrophic lateral sclerosis & frontotemporal degeneration. 11/2013;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disorder that causes muscle weakness, disability, respiratory failure, and eventually death. However, some ALS patients are diagnosed only after developing respiratory failure. To study the reason for delayed diagnosis of ALS, we reviewed cases of ALS patients with respiratory failure. We retrospectively reviewed all 200 patients diagnosed with sporadic ALS in our hospital from January 2001 to April 2011. Among them, we focused on seven patients who were diagnosed only after developing respiratory failure. We reviewed their clinical characteristics and demographics. The mean time from onset to a correct diagnosis was 15.6 ± standard deviation of 8.0 months. Two patients had already been intubated at a previous hospital because they presented with severe respiratory failure and required emergency intubation. One patient was intubated upon arrival to our hospital. We identified three reasons for the delay in diagnosis: delayed referral to a neurologist (four patients); a shortage of neurologists in rural areas (three patients); and an atypical clinical course with respiratory failure as the initial symptom (two patients). Three patients had undergone emergency intubation without giving informed consent. To provide an informed choice and to avoid unwanted intubation for ALS patients, we suggest extending neurological knowledge of ALS to general practitioners.
    Journal of Clinical Neuroscience 01/2014; · 1.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Amyotrophic lateral sclerosis (ALS) research is advancing quickly, but the transition from phase II to phase III trials remains particularly challenging. In part, this is because of the paradox of phase II ALS trials - they are expected to inform researchers about safety, tolerability, dosage selection, and efficacy using a small number of patients, and relying on essentially the same outcome measures used in phase III trials. We examined pharmacokinetics in the cerebrospinal fluid and pharmacodynamic markers to demonstrate target engagement. In addition, primary outcome measures are often not specified or do not reach pre-specified goals for significance. We conclude that future trials should include pharmacokinetic (preferably in CSF) and pharmacodynamic markers of target engagement when possible. Primary endpoints should be pre-specified. Inclusion criteria should be used to reduce heterogeneity and target a relevant subpopulation of people with ALS when possible. Multiple phase II trials might be required before moving to a large phase III trial.
    Amyotrophic lateral sclerosis & frontotemporal degeneration. 03/2014; 15(1-2):1-8.